Publications by authors named "Hai-Ying Dang"
Expert Opin Drug Saf
April 2024
Article Synopsis
- - Bimekizumab is a monoclonal antibody that targets interleukin-17A and IL-17F, showing promise in treating Psoriatic arthritis (PsA).
- - A systematic review of 4 randomized controlled trials (RCTs) with 892 PsA patients found that bimekizumab significantly improved skin and joint symptoms compared to placebos, although there was a slight increase in overall adverse events.
- - The study concluded that bimekizumab offers meaningful clinical benefits for PsA management while maintaining an acceptable safety profile.
